{"entity":{"id":"crebbp","kind":"target","name":"CREBBP","aka":["CREB binding lysine acetyltransferase ","CREB-binding protein","KAT3A"],"tldr":"CREBBP (CREB-binding protein) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Bladder & urothelial cancer, Leukaemia and 5 more.","summary":"Acetylates histones, giving a specific tag for transcriptional activation. Mediates acetylation of histone H3 at 'Lys-18' and 'Lys-27' (H3K18ac and H3K27ac, respectively). Also acetylates non-histone proteins, like DDX21, FBL, IRF2, MAFG, NCOA3, POLR1E/PAF53 and FOXO1.\n\nCIViC holds 5 clinical evidence items and 0 assertions across 4 variants, naming MTOR Inhibitor, C646, HDAC Inhibitor OBP-801 and Therapeutic Glucocorticoid. Open Targets scores its association with cancer at 0.83 (direct and indirect evidence; datatypes clinical 0.16, affected pathway 0.84, literature 0.99, genetic association 0.20, somatic mutation 0.97, animal model 0.58). IntOGen calls it a driver in 42 cohorts (12 activating, 29 loss-of-function), covering Acute Lymphoblastic Leukaemia, Basal Cell Carcinoma, Bladder/Urinary Tract, Bladder Urothelial Carcinoma, Invasive Breast Carcinoma, Renal Clear Cell Carcinoma and others.","asOf":"2026-09-23","links":[{"label":"HGNC HGNC:2348","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2348"},{"label":"UniProt Q92793","url":"https://www.uniprot.org/uniprotkb/Q92793/entry"},{"label":"NCBI Gene 1387","url":"https://www.ncbi.nlm.nih.gov/gene/1387"},{"label":"Ensembl ENSG00000005339","url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000005339"}],"tags":["cancer-genes-wave"],"related":["civic","open-targets","intogen"],"cancers":["non-hodgkin-lymphoma","urothelial","leukaemia","neuroendocrine","esophageal","breast-cancer","hcc","head-and-neck"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: Open Targets known-drug datatype score 0.16; IntOGen calls it an activating (Act) driver in 12 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 29 cohorts; CIViC holds 5 clinical evidence items on its variants; UniProt disease notes describe a translocation or gene fusion involving the gene. Evidence tier \"clinical-evidence\" is the strongest of those signals.","Prevalence not recorded: none of the sources gives a positivity rate."],"provenance":{"editedBy":"scripts/fetch-cancer-genes.ts (CIViC, Open Targets, IntOGen, HGNC, UniProt)","editedOn":"2026-09-23"},"symbol":"CREBBP","role":["drug-target","oncogene-driver","tumour-suppressor","biomarker","fusion-partner"],"evidenceTier":"clinical-evidence","sources":[{"label":"HGNC HGNC:2348","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2348","note":"approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)"},{"label":"UniProt Q92793","url":"https://www.uniprot.org/uniprotkb/Q92793/entry","note":"protein name, function text, keywords and locations (REST API)"},{"label":"CIViC gene CREBBP","url":"https://civicdb.org/features/1193","note":"5 evidence items, 0 assertions, 4 variants; diseases: Lung Non-small Cell Carcinoma, Acute Lymphoblastic Leukaemia, Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Lymphoma (GraphQL API, CC0)"},{"label":"Open Targets ENSG00000005339","url":"https://platform.opentargets.org/target/ENSG00000005339/associations","note":"association with cancer (MONDO_0004992) 0.83; per-cancer scores at or above 0.5: colorectal cancer 0.57, oesophageal cancer 0.54, urinary bladder cancer 0.66, ovarian cancer 0.53, melanoma 0.55, neuroendocrine neoplasm 0.60 (GraphQL API, CC0)"},{"label":"IntOGen CREBBP","url":"https://www.intogen.org/search?gene=CREBBP","note":"driver in 42 cohorts (Act 12, LoF 29); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0"}],"hgnc":"HGNC:2348","ensembl":"ENSG00000005339","uniprot":"Q92793","entrez":"1387","biology":"Acetylates histones, giving a specific tag for transcriptional activation. Mediates acetylation of histone H3 at 'Lys-18' and 'Lys-27' (H3K18ac and H3K27ac, respectively). Also acetylates non-histone proteins, like DDX21, FBL, IRF2, MAFG, NCOA3, POLR1E/PAF53 and FOXO1. Binds specifically to phosphorylated CREB and enhances its transcriptional activity toward cAMP-responsive genes. Acts as a coactivator of ALX1. Acts as a circadian transcriptional coactivator which enhances the activity of the circadian transcriptional activators: NPAS2-BMAL1 and CLOCK-BMAL1 heterodimers. Location: Cytoplasm; Nucleus (UniProt). Locus 16p13.3 (HGNC).","whereFound":["Non-Hodgkin lymphoma: Open Targets association 0.74 with non-Hodgkin lymphoma (MONDO_0018908); CIViC evidence names this disease","Bladder & urothelial cancer: Open Targets association 0.66 with urinary bladder cancer (MONDO_0001187); IntOGen driver in 7 cohorts (BLADDER, BLCA, UTUC)","Leukaemia: Open Targets association 0.65 with leukaemia (MONDO_0005059)","Neuroendocrine tumours: Open Targets association 0.60 with neuroendocrine neoplasm (MONDO_0019496); IntOGen driver in 1 cohort (NETNOS)","Oesophageal cancer: Open Targets association 0.54 with oesophageal cancer (MONDO_0007576); IntOGen driver in 2 cohorts (ESCA)","Breast cancer: Open Targets association 0.51 with breast cancer (MONDO_0007254); IntOGen driver in 2 cohorts (BRCA)"],"targetClass":"transcription","prevalence":[]},"route":"/targets/crebbp/","neighbours":{"collection":[{"id":"civic","kind":"collection","name":"CIViC","route":"/collections/civic/"},{"id":"intogen","kind":"collection","name":"IntOGen","route":"/collections/intogen/"},{"id":"open-targets","kind":"collection","name":"Open Targets Platform","route":"/collections/open-targets/"}],"cancer":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"},{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"},{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"},{"id":"leukaemia","kind":"cancer","name":"Leukaemia (all types)","route":"/cancers/leukaemia/"},{"id":"neuroendocrine","kind":"cancer","name":"Neuroendocrine tumours","route":"/cancers/neuroendocrine/"},{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"},{"id":"esophageal","kind":"cancer","name":"Oesophageal cancer","route":"/cancers/esophageal/"}]}}